2100 SE BLUE PARKWAY • LEE'S SUMMIT, MISSOURI 64063 • (816) 282-5000

Lee's Summit℠
MEDICAL CENTER
Your HCA Midwest Hospital

January 8, 2008

U.S. Nuclear Regulatory Commission Region III
Materials Licensing Branch
2343 Warrenville Road Suite 210
Lisle, IL 60532-4352

RE: Amendment Request

License No. 24-24660-01

Dear Sirs,

We wish to add the following two physicians to our license:

1. Wendall Doronio M.D. for 10 CFR 35.100, 35.200, 35.300. Enclosed is a copy of his American Board of Radiology and Kansas Radioactive Material License # 19-B296-01.
2. Vandana Halder M.D. for 10 CFR 35.100, 35.200, 35.300. Enclosed is a copy of her American Board of Radiology and Training and Experience Authorized User supplement A & B.

If you have any questions concerning this, please do not hesitate to contact us at 816-282-5624.

Sincerely,

Tracy R. Miller
Director of Imaging Services

RECEIVED JAN 15 2008

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Therapeutic Radiology and Oncology,
and the Association of University Radiologists
Hereby certifies that

Wendell P. Doronio, M.D.

Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of
The American Board of Radiology
On this eleventh day of December, 1989
Thereby demonstrating to the satisfaction of the Board
that he is qualified to practice the specialty of

Diagnostic Radiology

THE AMERICAN BOARD OF RADIOLOGY
INCORPORATED IN THE DISTRICT OF COLUMBIA
1934

Robert G. Parker
President

Secretary

AMERICAN BOARD
1989
OF
MEDICAL SPECIALTIES

RODERICK L. BREMBY, SECRETARY

KANSAS

DEPARTMENT OF HEALTH AND ENVIRONMENT

KATHLEEN SEBELIUS, GOVERNOR

November 1, 2005

MR. FRANK DEVOCELLE CEO
OLATHE MEDICAL CENTER
20333 W 151ST STREET
OLATHE, KS 66061

Dear Mr. Devocelle:

Enclosed is your amendment number 32, for Kansas Radioactive Materials License, number 19-B296-01. The changes made to your license are in **bold face type.** Please review the license carefully and contact this office if any problems are noted.

If you have any questions concerning this or any other matter, please do not hesitate to contact this office at 785-296-1560.

Sincerely,

James A. Harris BS RRPT
Radiation Control Inspector
Bureau of Air & Radiation
Radiation Control Program

Enclosure

DIVISION OF ENVIRONMENT
Bureau of Air & Radiation
Radiation and Asbestos Control Section
CURTIS STATE OFFICE BUILDING, 1000 SW JACKSON ST., STE 310, TOPEKA, KS 66612-1366
Voice 785-296-1560 Fax 785-296-0984 http://www.kdhe.state.ks.us/radiation

STATE OF KANSAS

RADIOACTIVE MATERIALS LICENSE

Pursuant to the Nuclear Development and Radiation Control Act (L. 1963, Ch. 290) and Kansas Annotated Regulations numbers 28-35-133 through 28-35-363 inclusive, and in reliance on statements and representations made to this agency by the licensee designated below, a license is hereby issued authorizing the licensee to transfer, receive, possess, and use the radioactive material or materials listed below; and to use such materials at the place or places listed below; and to use the material for the purpose or purposes listed below. This license is subject to all applicable rules, regulations, and orders now in effect or placed in effect by the Department of Health and Environment and any conditions specified below.

Amendment No. 32

Licensee	3. License number
1. Name Olathe Medical Center	19-B296-01
2. Address 20333 W. 151st Street Olathe KS 66061	4. Expiration date October 31, 2013
	5. Reference number

6. Radioactive materials (element and mass number)	7. Chemical and/or physical form	8. Maximum quantity licensee may possess at any one time
See Page No. 2	See Page No. 2	See Page No. 2

CONDITIONS

9. Authorized use. (Unless otherwise specified, the authorized place of use is the licensee's address stated in Item 2 above.)

A. Any diagnostic procedure listed in Groups I and II, Schedule D, Regulation 28-35-199a of the Kansas Radiation Protection Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III, Schedule D, Regulation 28-35-199a of the Kansas Radiation Protection Regulations.

C. Any therapeutic procedure listed in Group IV, Schedule D, Regulation 28-35-199a of the Kansas Radiation Protection Regulations.

D. Any therapeutic procedure listed in Group V, Schedule D, Regulation 28-35-199a of the Kansas Radiation Protection Regulations.

E. Any procedure listed in Group VI, Schedule D, Regulation 28-35-199a of the Kansas Radiation Protection Regulations.

F. through I. **To be used for calibration, transmission, reference and quality control.**

J. To be used for diagnostic studies involving imaging and tumor localizations.

STATE OF KANSAS

RADIOACTIVE MATERIALS LICENSE

Supplementary Sheet

License number: 19-B296-01

6. Radioactive materials (element and mass number)	7. Chemical and/or physical form	8. Maximum quantity licensee may possess at any one time
A. Any radioactive material listed in Groups I and II, Schedule D, Regulation 28-35-199a of the Kansas Radiation Protection Regulations.	A. Any radiopharmaceutical listed in Groups I and II, Schedule D, Regulation 28-35-199a of the Kansas Radiation Protection Regulations.	A. As necessary for uses authorized in Subitem 9.A.
B. Any radioactive material listed in Group III, Schedule D, Regulation 28-35-199a of the Kansas Radiation Protection Regulations.	B. Any form listed in Group III, Schedule D, Regulation 28-35-199a of the Kansas Radiation Protection Regulations.	B. 2.5 curies of each radioactive material authorized in Subitem 6.B.
C. Any radioactive material listed in Group IV, Schedule D, Regulation 28-35-199a of the Kansas Radiation Protection Regulations.	C. Any radiopharmaceutical listed in Group IV, Schedule D, Regulation 28-35-199a of the Kansas Radiation Protection Regulations.	C. 100 millicuries of each radioactive material authorized in Subitem 6.C.
D. Any radioactive material listed in Group V, Schedule D, Regulation 28-35-199a of the Kansas Radiation Protection Regulations.	D. Any radiopharmaceutical listed in Group V, Schedule D, Regulation 28-35-199a of the Kansas Radiation Protection Regulations.	D. 250 millicuries of each radioactive material authorized in Subitem 6.D.

STATE OF KANSAS

RADIOACTIVE MATERIALS LICENSE

Supplementary Sheet License number: 19-B296-01

6. Radioactive materials (element and mass number)	7. Chemical and/or physical form	8. Maximum quantity licensee may possess at any one time
E. Any radioactive material listed in Group VI, Schedule D, Regulation 28-35-199a of the Kansas Radiation Protection Regulations.	E. Any form listed in Group VI, Schedule D, Regulation 28-35-199a of the Kansas Radiation Protection Regulations.	E. 1.0 curie of each radioactive material authorized in Subitem 6.E.
F. Cobalt-57	F. **Any sealed source authorized by 10 CFR 35.65 or equivalent agreement state regulation.**	F. No single source to ~~exceed 25 millicuries~~
G. Cobalt-60	G. Sealed sources (DuPont NES-354; Isotope Products RV-060 or **equivalent source approved by the NRC or an agreement state)**	G. No single source to exceed 50 millicuries.
H. Germanium-68	H. **Any sealed source authorized by 10 CFR 35.65 or equivalent agreement state regulation.**	H. 45 millicuries total, no single source to exceed 13 millicuries.
I. Samarium-153	**I. Samarium chloride (DuPont NES-8153)**	**I. No single source to exceed 250 millicuries.**
J. Fluorine-18	J. Fluorodeoxyglucose (FDG)	J. 2 curies
K. Strontium-90	K. Sealed source (Bebig Sr0.S03; AEA Technology SICW series)	K. No single source to exceed 5 millicuries, 800 millicuries total

STATE OF KANSAS

RADIOACTIVE MATERIALS LICENSE

Supplementary Sheet License number: 19-B296-01

K. To be used in the Novoste Model A1000 series transfer device for intravascular brachytherapy.

10. Radioactive materials shall only be used at 20333 W. 151st Street, Olathe, Kansas and includes the mobile coach in the ambulance garage for fluorine-18 and germanium-68 only.

11. A. The Radiation Safety Officer in this program shall be Paul L. Chesis, M.D.

B. The alternate Radiation Safety Officer shall be Patrick Santiago, M.D.

12. A. Radioactive material listed in Item 6 above is authorized for use by the following individual(s) for the materials and uses indicated:

William Brooks, M.D.	**Subitems A., B., C. and F. through J.**
Craig M. Bruner, M.D.	**Subitems A., B., C., D. and F. through J.**
Paul L. Chesis, M.D.	**Subitems A., B., C., D, and F. through J.**
Susan Chow, M.D.	**Subitems A., B., C., D. and F. through J.**
Howard M. Cloogman, M.D.	**Subitems A., B., C., D. and F. through J.**
Ira Cox, M.D.	**Subitems A., B., C. and F. through J.**
Scott C. Cozad, M.D.	**Subitems C. through I. and K.**
W. B. Davis, M.D.	**Subitems A., B., C. and F. through J.**
Dion Depalois, M.D.	**Subitems A., B. and F. through J.**
Wendell Doronio, M.D.	**Subitems A., B. and F. through J.**
Kelly Hart, M.D.	**Subitems A., B., C. and F. through J.**
Bradley H. Koffman, M.D.	**Subitems C. through I. and K.**
Vickie L. Massey, M.D.	**Subitems C. through I. and K.**
Craig McClure, M.D.	**Subitems A., B. and F. through J.**
Gayle P. Miller, M.D.	**Subitems C. through I. and K.**
Rick Moritz, M.D.	**Subitems A., B., C. and F. through J.**
Jay Murphy, M.D.	**Subitems A., B. and F. through J.**
Douglas W. Nemmers, M.D.	**Subitems A., B., C., D. and F. through J.** (except Phosphorus-32)
Stephen S. Nigh, M.D.	**Subitems C. through I. and K.**
Steven D. Obermueller, M.D.	**Subitems A., B. and F. through J.**
Michael B. Parsa, M.D.	**Subitems A., B., C., D. and F. through J.**
Jay Robinow, M.D.	**Subitems C. through I. and K.**
Patrick Santiago, M.D.	**Subitems A., B. and F. through J.**
Sarah L. Sherard, M.D.	**Subitems A., B., C., D. and F. through J.**
Steven Smalley, M.D.	**Subitems E. through I. and K.**
Donald Stallard, M.D.	**Subitems A., B., C. and F. through J.**
Steve S. Whitfield, M.D.	**Subitems A., B. and F. through J.**
Robert Armacost Wood, M.D.	**Subitems A., B., C., D. and F. through J.**
Tom Zinn, M.D.	**Subitems A., B., C. and F. through J.**

STATE OF KANSAS

RADIOACTIVE MATERIALS LICENSE

Supplementary Sheet License number: 19-B296-01

B. **Radioactive material in subitem K of items 6, 7 and 8 shall be used in the physical presence of an authorized user or a medical physicist.**

13. A. (1) Each sealed source containing radioactive material, other than Hydrogen-3, with a half-life greater than thirty (30) days and in any form other than gas shall be tested for leakage and/or contamination at intervals not to exceed six (6) months. In the absence of a certificate from a transferor indicating that a test has been made within six (6) months prior to the transfer, a sealed source received from another person shall not be put into use until tested.

(2) Notwithstanding the periodic leak test required by this condition, any radioactive sealed source is exempt from such leak tests when the source contains 100 microcuries or less of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material.

(3) The periodic leak test required by this condition does not apply to sealed sources that are stored and not being used. The sources excepted from this test shall be tested for leakage prior to any use or transfer to another person unless they have been leak tested within six (6) months prior to the date of use or transfer. Sources in storage shall be physically inventoried every six months and listed in the radioactive materials inventory.

B. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. The test sample shall be taken from the sealed source or from the surfaces of the device in which the sealed source is permanently mounted or stored on which one might expect contamination to accumulate. Records of leak test results shall be kept in units of microcurie and maintained for inspection by the Radiation Control Program, Bureau of Air and Radiation, Kansas Department of Health and Environment.

C. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the licensee shall immediately withdraw the sealed source from use and shall cause it to be decontaminated and repaired or to be disposed of in accordance with Radiation Control Program, Bureau of Air and Radiation, Kansas Department of Health and Environment regulations. A report shall be filed within five (5) days of the test with the Radiation Control Program, Bureau of Air and Radiation, Kansas Department of Health and Environment, describing the equipment involved, the test results and the corrective action taken.

D. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically authorized by the Radiation Control Program, Bureau of Air and Radiation, Kansas Department of Health and Environment, the United States Nuclear Regulatory Commission, or an Agreement State to perform such services.

14. **The use of radioactive material in or on humans shall be by a physician.**

STATE OF KANSAS

RADIOACTIVE MATERIALS LICENSE

Supplementary Sheet License number: 19-B296-01

15. Sealed sources containing radioactive material shall not be opened.

16. The licensee shall conduct a physical inventory every six (6) months to account for all sealed sources received and possessed under the license. The records of the inventories shall be maintained for two years from the date of the inventory for inspection by the Radiation Control Program, Bureau of Air and Radiation, Kansas Department of Health and Environment, and shall include the quantities and kinds of radioactive material, location of sealed sources, and the date of the inventory.

17. A. Radiopharmaceuticals dispensed and/or distributed for human use shall be either:

(1) Repackaged from prepared radiopharmaceuticals that are the subject of an FDA-approved "New Drug Application" (NDA) or for which FDA has accepted a "Notice of Claimed Investigational Exemption for a New Drug" (IND), or

(2) Prepared from generators and reagent kits that are the subject of an FDA-approved NDA or for which FDA has accepted an IND.

(3) PET radiopharmaceuticals for which an NDA or IND is not required and shall fully comply with all USP standards and monographs pertaining to PET drugs.

B. Prepared radiopharmaceuticals for which FDA has accepted an IND and radiopharmaceuticals prepared from generators or reagent kits for which FDA has accepted an IND shall be dispensed and/or distributed:

(1) In accordance with the directions provided by the sponsor of the IND, and

(2) Only to physicians who have been accepted by the sponsor of the IND to participate in clinical evaluation of the drug.

The licensee shall inform, in writing, each physician who participates in an IND evaluation, that the physician is responsible to the sponsor of the IND for use of the drug in accordance with protocols established by the sponsor and for reporting to the sponsor the clinical information obtained through use of the drug.

18. A. The licensee shall perform a test to detect and quantify the activity of Molybdenum-99 contamination in each elution of Technetium-99m from a Molybdenum-99/Technetium-99m generator and in each extraction or separation of Technetium-99m from Molybdenum-99 not contained in a generator.

STATE OF KANSAS

RADIOACTIVE MATERIALS LICENSE

Supplementary Sheet License number: 19-B296-01

B. The licensee shall not distribute for human use Technetium-99m that, at the expiration date and time shown on the package label, contains more than 0.15 microcuries of Molybdenum-99 per millicurie of Technetium-99m or more than five (5) microcurie of Molybdenum-99 per dose of Technetium-99m. The expiration date and time shown on the package label shall be such that the limits above are not exceeded for any single patient dose. The limits for Molybdenum-99 contamination represent maximum values and Molybdenum-99 contamination should be kept as low as reasonably achievable below these limits.

C. The licensee shall establish written procedures for personnel performing tests to detect and quantify Molybdenum-99 contamination. These procedures shall include all necessary calculations and steps to be taken if activities of Molybdenum-99 in excess of the limits specified in Subitem B above are detected.

D. Personnel performing tests to detect and quantify Molybdenum-99 contamination shall be given specific training in performing these tests prior to conducting such tests.

E. (1) The licensee shall maintain for inspection by the Radiation Control Program, Bureau of Air and Radiation, Kansas Department of Health and Environment records of the results of each test performed to detect and quantify Molybdenum-99 contamination and records of training given to personnel performing these tests.

(2) Records described in E(1) above shall be maintained for three (3) years following the performance of the tests and training of personnel.

19. The licensee shall elute generators and process radioactive material with reagent kits in accordance with instructions furnished by the manufacturer on the label attached to or in the leaflet or brochure that accompanies the generator or reagent kit.

20. Patients containing therapeutic quantities of radiopharmaceuticals shall remain hospitalized until the residual activity is thirty (30) millicuries or less.

21. Patients containing temporary interstitial or brachytherapy implants shall remain hospitalized until surveys made with an appropriate radiation detection instrument indicate all implants have been removed. The results of these surveys shall be recorded and maintained for inspection by the Radiation Control Program, Bureau of Air and Radiation, Kansas Department of Health and Environment.

2. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.

STATE OF KANSAS

RADIOACTIVE MATERIALS LICENSE

Supplementary Sheet License number: 19-B296-01

B. Before disposal as normal waste, radioactive waste shall be surveyed to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.

23. Specific requirements for the Novoste Beta-Cath Intravascular Brachytherapy System:

A. Prior to each use of the Beta-Cath System on a human subject, a catheter integrity evaluation ("dummy" run) shall be conducted outside of the subject's body to allow the clinician to simulate a clinical procedure with non-radioactive sources.

B. Each intravascular brachytherapy device shall be inspected and serviced at intervals established by the manufacturer. Maintenance and repair shall be performed only by the manufacturer or persons specifically authorized by the Nuclear Regulatory Commission or an Agreement State to perform such services.

24. The licensee may transport radioactive material or deliver radioactive material to a carrier for transport, in accordance with the provisions of Kansas Radiation Protection Regulations 28-35-196a, "Preparation of Radioactive Material for Transport".

25. The licensee shall comply with the provisions of Kansas Radiation Protection Regulations, Part 4, "Standards for Protection Against Radiation" and Part 10, "Notices, Instructions and Reports to Workers; Inspections."

26. The licensee shall possess and use radioactive material described in Items 6, 7 and 8 of this license according to the most restrictive of, the Kansas Radiation Protection Regulations, this license or statements, representations, and procedures contained in the following documents:

(a) The letter dated February 9, 2004, signed by Ron Galloway, with attachment.

(b) The letter dated August 4, 2004, signed by Ron Galloway, with attachment.

(c) The electronic mail dated September 7, 2004, from Ron Galloway.

(d) The fax dated September 30, 2005, from Dr. Paul Chesis.

(e) The letter dated September 27, 2005, signed by Lucretia Craig.

FOR THE STATE DEPARTMENT OF HEALTH AND ENVIRONMENT

Date NOV 23 2005

By: _____

Thomas A. Conley, CHP
Radiation Control Program

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Therapeutic Radiology and Oncology, the Association of
University Radiologists, and American Association of Physicists in Medicine

Hereby certifies that

Vandana Halder, MD

Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of
The American Board of Radiology
On this sixth day of June, 2007
Thereby demonstrating to the satisfaction of the Board
that she is qualified to practice the specialty of

Diagnostic Radiology

AM Eligible

THE AMERICAN BOARD OF RADIOLOGY
INCORPORATED IN THE DISTRICT OF COLUMBIA
1934

Certificate No. 53305

President

Secretary-Treasurer

Executive Director

AMERICAN BOARD OF RADIOLOGY

Valid through 2017

SUPPLEMENT — U.S. NUCLEAR REGULATORY COMMISSION

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER	2. FOR PHYSICIANS, STATE OR TERRITORY WHERE LICENSED
Vandana Halder, M.D.	KS & MO

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C
American Board of Radiology	Diagnostic Radiology	~~written~~ + physics ↓ Sept '06 → oral Boards ~~not~~ - June '07 passed

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING: CLOCK HOURS IN LECTURE OR LABORATORY	TYPE AND LENGTH OF TRAINING: CLOCK HOURS OF SUPERVISED ON-THE-JOB EXPERIENCE
a. RADIATION PHYSICS AND INSTRUMENTATION			
b. RADIATION PROTECTION			
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY			
d. RADIATION BIOLOGY			
e. RADIOPHARMACEUTICAL CHEMISTRY			

5. EXPERIENCE WITH RADIATION. *(Actual use of Radioisotopes or Equivalent Experience)*

ISOTOPE	mCi USED AT ONE TIME	LOCATION	CLOCK HOURS	TYPE OF USE
I^{131}	ranging from 18 mci to 150 mci	TMC.	—	Thyroid ablation for hyperthyroidism and cancer.

EXHIBIT 3

SUPPLEMENT B

SUPPLEMENT — U. S. NUCLEAR REGULATORY COMMISSION

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. PROPOSED PHYSICIAN USER'S NAME AND ADDRESS

FULL NAME: Vandana Halder, M.D.

STREET ADDRESS: 5800 Foxridge Dr., Ste 240

CITY: Mission | STATE: KS | ZIP CODE: 66202

KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS [Additional information or comments may be submitted in duplicate on separate sheets.] D
	Thyroid scan	34	
	Thyroid uptake	34	
	Lung perfusion scan	45	
	Xenon ventilation study	—	
	Aerosol ventilation scan	45	
	Renal flow scan	13	
	Brain scan	—	
	Liver/spleen scan	—	
	Bone scan	47	
	Gastroesophageal study	—	
	LeVeen shunt study	—	
	Cystogram	—	
	Dacryocystogram	—	
	Cardiac perfusion scan	—	
	Cardiac stress ventriculogram	—	
	Cardiac rest ventriculogram	—	
	Gallium scan	—	
	MUGA Scan	4	
	Hepato-Biliary Scan	18	
	Gastric Emptying	17	
	Parathyroid Imaging	8	

PROPOSED PHYSICIAN USER
Vandana Halder, M.D.

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheet.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	—	
P-32 (Colloidal)	INTRACAVITARY TREATMENT	—	
I-131	TREATMENT OF THYROID CARCINOMA	4	
	TREATMENT OF HYPERTHYROIDISM	8	
Au-198	INTRACAVITARY TREATMENT	—	
Co-60 or Cs-137	INTERSTITIAL TREATMENT	—	
	INTRACAVITARY TREATMENT	—	
I-125 or Ir-192	INTERSTITIAL TREATMENT	—	
Co-60 or Cs-137	TELETHERAPY TREATMENT	—	
Sr-90	TREATMENT OF EYE DISEASE	—	
	RADIOPHARMACEUTICAL PREPARATION	—	
Mo-99/ Tc-99m	GENERATOR	—	
Sn-113/ In-113m	GENERATOR	—	
Tc-99m	REAGENT KITS	—	
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

LOCATION	DATES	CLOCK HOURS OF EXPERIENCE

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR
Dr Gerald Finke

b. NAME OF INSTITUTION
Truman medical center

c. MAILING ADDRESS
2301 Holmes Street

d. CITY
KC MO 64108

e. MATERIALS LICENSE NUMBER(S)

5. PRECEPTOR'S SIGNATURE

7. PRECEPTOR'S NAME (Please type or print)
LISA H. LOWE MD

8. DATE
07/01/07

Lee's Summit Medical Center
2100 S E Blue Parkway
Lee's Summit MO 64063

$ 01.31°

U.S. Nuclear Regulatory Commission Reg III
Materials Licensing Branch
2343 Warrenville Road Suite 210
Lisle, IL 60532-4352